Where I see patients (1)
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With G...
Will be calculated as the number of days from the date of patient registration to the date of death.
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Overall survival is defined from the time of randomization to death from any cause. Patients still alive at the time of an analysis will be considered censored at their date of last contact.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Overall Survival is defined as the time from randomization to death due to any cause.
AB154 Combined With AB122 for Recurrent Glioblastoma
Adverse events will be listed individually by patient and treatment group. The number of patients experiencing each adverse event will be summarized by organ and grade. The number and percentage of patients with adverse events in ...
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Number of Participants with a Dose-Limiting Toxicity (DLT)
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patien...
The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3 (higher scores indicating more anxiety).
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Pati...
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Occurrence of DLTs by Incidence of TEAEs and SAEs, as assessed by NCI CTCAE v5.0